ArticleInternational ophthalmology2025
Effectiveness of a split-dose, twice-daily low-dose atropine monocular treatment in children with anisometropia: a retrospective study.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-Term Outcomes and Predictors of Stepwise Atropine Concentration Adjustment in Paediatric Myopia Management.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- The Changing Natural History of Anisometropia: A Scoping Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTo evaluate the efficacy of a split-dose, twice-daily atropine treatment with 0.05% atropine administered at bedtime and 0.025% atropine administered in the late afternoon in reducing interocular differences in spherical equivalent (SE) and axial length (AL) in children with myopic or mixed anisometropia.
methodsMedical records of 39 children with anisometropia who received 0.05% atropine at bedtime and 0.025% atropine in the late afternoon for the eye with longer AL were retrospectively reviewed. Participants were divided into younger (5-7 years) and older (8-9 years) groups according to age at treatment initiation, or into myopic and mixed anisometropia groups according to anisometropia type. Ophthalmologic examinations were performed every six months over an average follow-up period of 4.2 years, with analyses focusing on changes in SE, AL, and interocular differences. Outcomes were compared based on anisometropia type and age at treatment initiation.
resultsInterocular SE difference significantly decreased from 3.15 to 1.53 D (mean change = 1.62 D, Cohen's d = 1.98, 95% CI = 1.36-1.88, p < 0.001), and interocular AL difference decreased from 1.07 mm to 0.54 mm over a 4.2 year period (mean change = 0.53 mm, Cohen's d = 1.66, 95% CI = 0.43-0.63, p < 0.001). Notably, 74.4% of participants reduced their SE difference to < 2.0 D, with 28.2% achieving a reduction to 1.0 D or less. Both myopic and mixed anisometropia groups demonstrated significant reductions in interocular differences of SE and AL, with no significant differences in annual changes of SE or AL. The younger group showed a more significant reduction in AL in the treated eye than the older group (p = 0.035). Near-vision impairment during near-work tasks was not observed.
conclusionA split-dose, twice-daily atropine regimen-comprising 0.05% at bedtime and 0.025% in the late afternoon-may be effective in reducing interocular differences in SE and AL in children with anisometropia, with good tolerability. Early initiation of treatment may be associated with more favorable outcomes in AL control. Further prospective studies are warranted to confirm these findings and evaluate long-term efficacy.
Indexed as
Identifiers
40549251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.